-

12:32:13 PM

BIXT Stock News

BIXT - Bioxytran Inc

09/14/23 9:41 AM

OTC : BIXT

Bioxytran Announces Broad Spectrum Antiviral Activity Highlighted in ProLectin-M

BIOXYTRAN, INC. ( BIXT), (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral diseases, announced that its preprint article titled “Evaluation of Complex Carbohydrates Showing

RHEA-AI

neutral

08/24/23 9:00 AM

OTC : BIXT

clinical trial

Bioxytran Announces FDA Clearance of its IND Application for ProLectin-M in Clinical Trials

BIOXYTRAN, INC. ( BIXT), (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral diseases, announced that it has received clearance of its

RHEA-AI

neutral

08/08/23 7:00 AM

OTC : BIXT

covid-19

Bioxytran Initiates a Registrational Trial of Oral ProLectin-M for Mild to Moderate COVID-19 Patients

BIOXYTRAN, INC. ( BIXT), (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral diseases, announced the initiation of a clinical trial to treat Mild to Moderate COVID-19 patients. The

RHEA-AI

neutral

07/31/23 7:00 AM

OTC : BIXT

management

Bioxytran Names Leslie Ajayi as Interim CMO and Head of the Medical Advisory Board

BIOXYTRAN, INC. ( BIXT), (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral diseases, announced that it named Leslie Ajayi, MD as its interim Chief Medical Officer and Chief of

RHEA-AI

neutral

06/27/23 7:00 AM

OTC : BIXT

covid-19

Bioxytran Peer-Reviewed Journal in “Vaccines” Contains Mechanism Capable of Targeting Future COVID-19 Mutations

BIOXYTRAN, INC. (

RHEA-AI

neutral

06/12/23 9:00 AM

OTC : BIXT

Bioxytran Expands Institutional Investor Base with an additional $500,000 Equity Investment

BIOXYTRAN, INC. ( BIXT), (the “Company”), a clinical stage biotechnology company developing anti-viral oral drugs to treat retroviruses like SARS-CoV-2 which cause COVID-19 and other

RHEA-AI

neutral

05/01/23 8:00 AM

OTC : BIXT

Bioxytran Interview at the Emerging Growth Conference

BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to

RHEA-AI

neutral

04/19/23 9:00 AM

OTC : BIXT

clinical trial

Bioxytran Tests Acellular Oxygen Carrier BXT-25 in Pre-Clinical Trials

BIOXYTRAN, INC. ( BIXT), (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral diseases, announced that its long awaited Acelluar Oxygen Carrier BXT-25 has been successfully tested

RHEA-AI

positive

04/03/23 3:04 PM

OTC : BIXT

Bioxytran Interview at the Emerging Growth Conference

BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat

RHEA-AI

neutral

03/29/23 7:00 AM

OTC : BIXT

clinical trial

Bioxytran Announces Positive Phase 2 Trial Results were Featured in “Vaccines” a Peer-Reviewed Journal

BIOXYTRAN, INC. (

RHEA-AI

neutral

BIXT Data

IndustryResearch and Development in Biotechnology
Websitehttps://www.bioxytraninc.com/
Security nameBioxytran Inc
SectorProfessional, Scientific, and Technical Services
Tags
- Pharmaceuticals: Major
- Health Technology
CountryUS

About Bioxytran Inc

bioxytran, inc., an early stage pharmaceutical company, focuses on the development, manufacture, and commercialization of various therapeutic drugs to address hypoxia in humans. the company's lead pharmaceutical drug candidate is bxt-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for the treatment of patients with ischemia of the brain resulting from a stroke or the blockage of the blood vessels to the brain. its products also include bxt-252, an injectable anti-necrosis drug to treat a wound that does not heal because limited amount of oxygen reaching the wound. the company was founded in 2017 and is headquartered in newton, massachusetts.